PURA Announces CBD Confections and CBD Pet Products Acquisitions On Track
February 26 2020 - 9:02AM
InvestorsHub NewsWire
PURA Announces CBD Confections and
CBD Pet Products Acquisitions On Track
Dallas, TX -- February 26, 2020 -- InvestorsHub
NewsWire -- Puration, Inc. (USOTC:
PURA) today announced its first two target acquisitions in an
overall acquisition campaign funded by a recent $5 million
investment remain on track. PURA anticipates closing the
acquisition of a CBD Infused Pet Products operation tomorrow,
Thursday, February 27th. A second acquisition of a CBD
Infused Confections operation is underway. PURA has engaged a
third party to produce a fairness opinion on the target CBD Infused
Confections operation acquisition as a next step in the
process. The fairness opinion is anticipated to be complete
next week with the completion of the acquisition to follow shortly
thereafter.
PURA
recently launched a campaign to acquire CBD infused beverage,
edible and topical operations and also announced closing on a $5
million investment to fund the acquisition campaign. The $5 million
investment is structured as a debt facility whereby funds can be
drawn as needed to fund acquisitions. The drawn funds would
be secured by the acquired asset and the debt can be repaid in
stock at $0.10 per share. The CBD Infused Pet Products
acquisition schedule tomorrow is the first in an anticipated series
of acquisitions. PURA is currently working to build a
pipeline of more acquisition opportunities.
For
more information on Puration, visit http://www.purationinc.com
Disclaimer/Safe Harbor:
This
news release contains forward-looking statements within the meaning
of the Securities Litigation Reform Act. The statements reflect the
Company's current views with respect to future events that involve
risks and uncertainties. Among others, these risks include the
expectation that any of the companies mentioned herein will achieve
significant sales, the failure to meet schedule or performance
requirements of the companies' contracts, the companies' liquidity
position, the companies' ability to obtain new contracts, the
emergence of competitors with greater financial resources and the
impact of competitive pricing. In the light of these uncertainties,
the forward-looking events referred to in this release might not
occur. These statements have not been evaluated by the Food and
Drug Administration. These products are not intended to diagnose,
treat, cure, or prevent any disease.
Contact:
Puration, Inc.
Brian Shibley,
info@aciconglomerated.com
(800)
861-1350
Puration (CE) (USOTC:PURA)
Historical Stock Chart
From Mar 2024 to Apr 2024
Puration (CE) (USOTC:PURA)
Historical Stock Chart
From Apr 2023 to Apr 2024